Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety

20260 citationsJournal Articlegold Open Access

Authors

Masakazu Kanamori · Chugai Pharma (United States)

Izumi Sato · Chugai Pharma (United States)

Christine X. Koo · Health Sciences Authority

Yang Sun

Hiroki Kawauchi · Chugai Pharma (United States)

Kenji Nakagawa · Chugai Pharma (United States)

Atsuko Murai · Chugai Pharma (United States)

Abstract

Selective blockade of latent TGF-β1 activation represents a promising approach for treating a broad range of fibrotic diseases and cancers. By specifically targeting TGF-β1, SOF10 may offer a safer and more effective therapeutic option compared to non-selective TGF-β inhibitors. This strategy has the potential to transform the treatment paradigm for fibrosis-related conditions.

Topics & Keywords

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Connective Tissue Growth Factor Research Systemic Sclerosis and Related Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Communications Medicine

Volume 6, Issue 1

DOI: 10.1038/s43856-026-01408-w

Field-Weighted Citation Impact: 0.00